← Back to Home

AI-Designed Proteins Enter Research Services: Monod Bio Licenses Technology to SignalChem for Custom Assay Development

Designed proteins that emit light and recognize targets are set to become new tools for customized experiments. This non-exclusive license brings the technology to a research services platform, but the announcement has yet to provide measured data on assay performance or faster drug discovery.

By SURL BioNews

Drug discovery requires more than candidate molecules; it also needs tools that reliably read out biological responses. On August 26, 2026, Monod Bio and SignalChem Biotech announced a licensing collaboration to incorporate AI-designed light-emitting and target-recognition proteins into custom research services, bringing these technologies to more research customers through existing experimental platforms.

The non-exclusive license covers Monod Bio’s LuxSit luciferase technology and NovoBodies. According to the companies’ announcement, SignalChem can use them in luminescence assays developed for third-party customers and in protein fusion services; the licensed uses are limited to research. SignalChem is a wholly owned subsidiary of Sino Biological, providing reagents and contract research services that support drug discovery and life science research.

The two types of proteins serve different roles. LuxSit is an enzyme designed from scratch using AI for use in luminescent biosensors; NovoBodies are small target-binding proteins that the company describes as highly stable. From an assay design perspective, recognizing a target and generating a measurable signal are two steps in converting molecular events into experimental readouts. However, the announcement did not specify which targets or assay configurations would be used in this collaboration.

Rob Burgess, Chief Business Officer of Sino Biological, said the goal of integrating the technologies is to help researchers obtain high-quality discovery candidate molecules more quickly and address complex biological questions. Company-supplied content published by News-Medical also identified custom assays and discovery workflows as intended applications. These statements describe the collaboration’s expected uses and cannot yet be regarded as demonstrated improvements in speed or quality.

The publicly available information on this collaboration did not include data on the new platform’s sensitivity, specificity, reproducibility, or comparisons with existing methods, nor did it detail the training data used for AI design or the scale of validation. What can currently be confirmed is therefore the technology license and the intended direction of service integration; its actual performance across different research settings cannot yet be assessed. A license for research use also does not establish that the technology has been approved for patient diagnosis.

For Monod Bio, the collaboration extends its “Monod Inside” model, in which partner companies incorporate designed proteins into commercial products and services. The transaction’s licensing fees, milestone payments, and royalty terms were not disclosed; Sino Biological also said that revenue from the related business is not expected to have a material impact on the group’s overall financial performance. The collaboration’s subsequent results will depend on whether the custom assays deliver reliable data and whether research customers adopt them.

References

  1. BioPharma APAC
  2. Monod Bio
  3. Sino Biological via PR Newswire
  4. News-Medical